Cochrane · systematic review · CD003559
Omalizumab for asthma in adults and children
Normansell, R, Walker, S, Milan, SJ, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
9
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 33.3%Moderate 6 · 66.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Subcutaneous omalizumab + steroid versus placebo + steroid (stable steroid) for asthma in adults and children
Population: adults and children with asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants with at least one exacerbation All asthmatic participants (16 to 60 weeks) Subcutaneous omalizumab + steroid vs placebo + steroid (stable steroid) | OR 0.55 [0.46, 0.65] | 10 studies · 3261 participants | Moderate Downgraded: risk of bias |
Number of participants with at least one exacerbation Moderate to severe asthma (16 to 60 weeks) Subcutaneous omalizumab + steroid vs placebo + steroid (stable steroid) | OR 0.5 [0.42, 0.6] | 7 studies · 2889 participants | Moderate Downgraded: risk of bias |
Number of participants with at least one exacerbation Severe asthma (16 to 32 weeks) Subcutaneous omalizumab + steroid vs placebo + steroid (stable steroid) | OR 1 [0.5, 1.99] | 2 studies · 277 participants | Low Downgraded: risk of bias, imprecision |
Mortality 16 to 60 weeks Subcutaneous omalizumab + steroid vs placebo + steroid (stable steroid) | OR 0.19 [0.02, 1.67] | 9 studies · 4245 participants | Low Downgraded: risk of bias, imprecision |
Hospitalisations 28 to 60 weeks Subcutaneous omalizumab + steroid vs placebo + steroid (stable steroid) | OR 0.16 [0.06, 0.42] | 4 studies · 1824 participants | Moderate Downgraded: risk of bias, imprecision |
Adverse event—serious 16 to 60 weeks Subcutaneous omalizumab + steroid vs placebo + steroid (stable steroid) | OR 0.72 [0.57, 0.91] | 15 studies · 5713 participants | Moderate Downgraded: risk of bias, imprecision |
Subcutaneous omalizumab + steroid versus placebo + steroid (steroid reduction) for asthma in adults and children
Population: adults and children with asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants achieving complete inhaled steroid withdrawal 28 to 32 weeks Subcutaneous omalizumab + steroid vs placebo + steroid (steroid reduction) | OR 2.5 [2, 3.13] | 4 studies · 1634 participants | Low Downgraded: risk of bias, inconsistency |
>50% reduction in inhaled steroid usage 28 to 32 weeks Subcutaneous omalizumab + steroid vs placebo + steroid (steroid reduction) | OR 2.5 [2.02, 3.1] | 4 studies · 1634 participants | Moderate |
Exacerbations requiring hospitalisation 28 weeks Subcutaneous omalizumab + steroid vs placebo + steroid (steroid reduction) | OR 0.11 [0.03, 0.48] | 3 studies · 1405 participants | Moderate Downgraded: risk of bias, inconsistency |